ABSTRACT TYPES   

During the online abstract submission, authors will be requested to select their preferred method of presentation: Oral or Poster Presentation or Poster only Presentation. 

Presentation method preferences will be considered during the review process.

SESSION THEMES (TOPICS)   

Themes (topics) for each of the sessions are listed below. Please submit your abstract within the Basic Science, Clinical or Public Health streams under one of the following subtopics: 

Basic-Translational
1.1 Basic-translational science – HBV/HDV immunology
1.2 Basic-translational science – HBV/HDV virology
1.3 Basic-translational science – HCV/flavivirus immunology
1.4 Basic-translational science – HCV/flavivirus virology
1.5 Basic-translational science – Hepatocellular carcinoma including viral carcinogenesis
1.6 Basic-translational science – Liver inflammation and fibrogenesis
1.7 Basic-translational science – Liver pathogen detection and discovery
1.8 Basic-translational science – Other viruses (including HEV)
1.9 Basic-translational science – Preclinical therapeutics HBV/HDV

Clinical
2.1 Clinical science – Approved and promising new HDV therapies and diagnostics
2.2 Clinical science – Approved HBV treatments
2.3 Clinical science – Therapies in development for HBV/HDV
2.4 Clinical science – Biomarkers for liver diseases
2.5 Clinical science – HBV screening, clinical care delivery and outcomes
2.6 Clinical science – HCV screening, clinical care delivery and outcomes
2.7 Clinical science – Hepatocellular carcinoma clinical
2.8 Clinical science – Other viruses, clinical and treatment
2.9 Clinical science – Viral hepatitis coinfections and morbidities: HIV, MASLD/MASH

Public Health
3.1 Public health – Epidemiology of HBV/HDV
3.2 Public health – Epidemiology of HCV
3.3 Public health – Epidemiology of hepatocellular carcinoma
3.4 Public health – HBV elimination: achievements and challenges
3.5 Public health – HCV elimination: achievements and challenges
3.6 Public health – Prevention of new infections, including vaccination and injection safety
3.7 Public health – Simplified community and clinic- based approaches to viral hepatitis care cascade
3.8 Public health – Strategies for equitable service delivery to overcome disparities in viral hepatitis
3.9 Public health – Health economics

The abstract review committee reserves the right to reassign submitted abstracts to a different session. 

ABSTRACT FORMATTING GUIDELINES  

Please adhere to the following formatting guidelines when submitting your abstracts for GHS 2027. Abstracts that are not correctly formatted will not be reviewed. 

• The abstract title should not exceed 300 characters 

• The abstracts should not exceed 3,000 characters 

• Each abstract is allowed to include a maximum of three (3) caption (figure or table) but this is not a requirement. Minimize the use of charts and graphics as this detail is not used to evaluate the merit of your abstract 

• There is no restriction on your abstract structure, but we recommended the following: 

• • Title 

• • Background 

• • Purpose 

• • Method(s) 

• • Result(s) 

• • Conclusion(s) 

NOTIFICATION OF ACCEPTANCE    

Presenting authors will be notified of their acceptance status in late December 2026. Presenting authors must inform any co-author(s) of acceptance. The organizing committee reserves the right to accept or decline any submissions and to select the presentation format (oral or poster). 

DISCLOSURE OF CONFLICTS OF INTEREST 

The presenting authors of abstracts selected for oral presentation will be required to complete and submit a Disclosure of Conflicts of Interest form after they are invited to present. Disclosures are due on or before the RSVP deadline. 

DISCLAIMER REGARDING THE SUBMISSION OF ABSTRACTS 

The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events. 

For any questions or assistance regarding abstract submissions, please contact:  GHSinfo@mci-agency.com